Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05094102 · ClinicalTrials.gov registry record · NA
Intraoperative Evaluation of Axillary Lymphatics
A NA study of Breast Cancer and Surgery, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- NA
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT05094102: Completed NA study of Breast Cancer and Surgery, sponsored by University of Wisconsin, Madison.
NCT05094102 is a NA study of Breast Cancer and Surgery that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 9 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05094102, a NA study of Breast Cancer and Surgery, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- NA
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will assess the feasibility of using the OnLume Imaging System for fluorescence-guided surgery along with indocyanine green (ICG) dye in the operating room for the axillary reverse mapping (ARM) procedure in women with breast cancer scheduled to have axillary dissection (AD) or sentinel lymph node (SLN) biopsy.
Primary Outcome
This measure will determine whether lymphatics were visualized (yes/no) by each modality during axillary reverse mapping
Conditions Studied
Interventions
- DRUG Indocyanine green
- DEVICE OnLume Imaging System
Study Locations (1)
Wisconsin
- University of Wisconsin School of Medicine and Public Health - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2022-05-05 |
| Est. Completion | 2023-04-27 |
| Phase | NA |
What the finished NCT05094102 record still lists
NCT05094102 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower).
The record links to 3 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Indocyanine green is the first listed.
NCT05094102 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT05094102 about?
NCT05094102 is a clinical study titled "Intraoperative Evaluation of Axillary Lymphatics". This study will assess the feasibility of using the OnLume Imaging System for fluorescence-guided surgery along with indocyanine green (ICG) dye in the operating room for the axillary reverse mapping (ARM) procedure in women with breast cancer scheduled to have axillary dissection (AD) or sentinel l...
What is the current status of trial NCT05094102?
This trial is currently completed. It is a NA study. The enrollment target is 9 participants. The study started on 2022-05-05. Estimated completion is 2023-04-27.
What conditions does trial NCT05094102 study?
This clinical trial studies the following conditions: Breast Cancer, Surgery, Lymphedema.
What interventions are being tested in trial NCT05094102?
The interventions under investigation include: Indocyanine green (DRUG), OnLume Imaging System (DEVICE).
Who is sponsoring clinical trial NCT05094102?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05094102 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05094102's enrollment target sits among peer trials
9 1190th of 1224 higher than 30 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI